-
Mashup Score: 2
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t sign in? Forgot your username? Background: Heart failure (HF) dramatically alters lifespan and quality of life (1). Screening for HF could potentially reduce HF incidence through targeted risk factor reduction but is not regularly used, in part because of the difficulty in identifying high-risk populations to screen. In 2023, widespread HF risk assessment
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t sign in? Forgot your username? Background: Heart failure (HF) dramatically alters lifespan and quality of life (1). Screening for HF could potentially reduce HF incidence through targeted risk factor reduction but is not regularly used, in part because of the difficulty in identifying high-risk populations to screen. In 2023, widespread HF risk assessment
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet-
On @ABCGMA3 yesterday, @DoctorDarienMD explained the findings of a new Annals paper describing population-wide risk for #HeartFailure using the PREVENT equations. Read the study here: https://t.co/KHv3a4pRjo https://t.co/l7xnqI1fPi
-
-
Mashup Score: 22
Marty Tam, MD, FACC
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet-
🗝️ Collecting a detailed family history and pertinent clinical data for patients with cardiomyopathies is needed to guide potential use of genetic testing. Read more key points on genetic testing for cardiomyopathies ➡️ https://t.co/3aNgt4FXw2 #HeartFailure
-
-
Mashup Score: 9
BACKGROUND: Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF. METHODS: This open-label study included 67 patients hospitalized with acute HF and renal dysfunction. Patients were randomized to standard care, low-dose intravenous BNP (0.005 µg/kg per minute), or combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours. The coprimary end points were the percent change in estimated glomerular filtration rate and blood urea nitrogen from baseline to 48 hours. RESULTS: Treatment with BNP and BNP/PDEV inhibitor significantly increased plasma cGMP at 24 hours (+25.6% [+9.8%,
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute #HeartFailure https://t.co/e3tjj6omdz @CircHF
-
-
Mashup Score: 12Reshaping the Use of Transcatheter Mitral Valve Repair in Patients With Heart Failure: the RESHAPE-HF2 Trial - American College of Cardiology - 10 day(s) ago
Despite Food and Drug Administration (FDA) approval of mitral valve transcatheter edge-to-edge repair (M-TEER) in 2013, its impact in patients with symptomatic heart failure (HF) and significant functional mitral regurgitation (MR) despite maximally tolerated guideline-directed medical therapy (GDMT) has remained in question. This uncertainty is partly due to contrasting results from previous trials such as the MITRA-FR (Percutaneous Repair With the MitraClip Device for Severe Functional/Secondary Mitral
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet-
The results of the RESHAPE-HF2 trial show that M-TEER is associated with a reduction in HF hospitalizations/death and improvement of symptoms. Read an expert analysis for more: https://t.co/V4XXcCJAtV #HeartFailure
-
-
Mashup Score: 6Impact of Kinlessness on Older Adults With Advanced HF: Key Points - American College of Cardiology - 17 day(s) ago
Christina Cantey, DNP, FNP-C, CCK, AACC
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet-
Get insights from a review on the negative impact kinlessness can have on older adults w/ advanced heart failure and potential solutions to the disparity of care. Learn more: 🔗 https://t.co/O7nOBJFj3v #HeartFailure
-
-
Mashup Score: 1Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/Parkin Pathway to Alleviate ISO-induced Cardiac Remodeling - PubMed - 17 day(s) ago
Heart failure has always been a prevalent, disabling, and potentially life-threatening disease. For the treatment of heart failure, controlling cardiac remodeling is very important. In recent years, clinical trials have shown that sodium-glucose cotransporter-2 (SGLT-2) inhibitors not only excel in …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
RT @JCVPOnline: Canagliflozin Alleviates Cardiac Remodeling via the AMPK/PINK1/Parkin Pathway https://t.co/O5mi4s25Gg #HeartFailure #Cardia…
-
-
Mashup Score: 70Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern? - 1 month(s) ago
Click on the article title to read more.
Source: dom-pubs.onlinelibrary.wiley.comCategories: General Medicine News, General HCPsTweet-
Important care gap highlighted by the EMPA KIDNEY post-trial follow up: 1 in 4 people with diabetes on SGLT2i who were hospitalised for #heartfailure didnt restart SGLT2i within 12 months of discharge SGLT2i discontinuation analysis led by @tamie_milder: https://t.co/AuANgQokZq
-
-
Mashup Score: 20Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency - American College of Cardiology - 1 month(s) ago
Dharam J. Kumbhani, MD, SM, FACC
Source: www.acc.orgCategories: General Medicine News, Cardiology News and JournTweet-
The goal of the IRONMAN trial was to evaluate the safety & efficacy of ferric derisomaltose on CV outcomes among patients w/ heart failure & iron deficiency. Read new updates to the trial on impact of baseline blood tests of anemia & more: https://t.co/4ikfSwP3KU #HeartFailure
-
-
Mashup Score: 9
BACKGROUND: Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF. METHODS: This open-label study included 67 patients hospitalized with acute HF and renal dysfunction. Patients were randomized to standard care, low-dose intravenous BNP (0.005 µg/kg per minute), or combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours. The coprimary end points were the percent change in estimated glomerular filtration rate and blood urea nitrogen from baseline to 48 hours. RESULTS: Treatment with BNP and BNP/PDEV inhibitor significantly increased plasma cGMP at 24 hours (+25.6% [+9.8%,
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute #HeartFailure https://t.co/e3tjj6omdz @CircHF
-
On @ABCGMA3 yesterday, @DoctorDarienMD explained the findings of a new Annals paper describing population-wide risk for #HeartFailure using the PREVENT equations. Read the study here: https://t.co/KHv3a4pRjo https://t.co/l7xnqI1fPi